SILK

Silk Road Medical to Report First Quarter 2024 Financial Results on April 30, 2024

Retrieved on: 
Tuesday, April 9, 2024
Risk, Webcast, SILK, Stroke

SUNNYVALE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, April 30th, 2024.

Key Points: 
  • SUNNYVALE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, April 30th, 2024.
  • Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Those interested in listening to the conference call should register online using this link .
  • Participants are encouraged to register more than 15 minutes before the start of the call.

Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS

Retrieved on: 
Tuesday, April 2, 2024
Neuroprotection, Risk, Stroke, FSVS, NPS, Workflow, Stenosis, FACS, SILK, Blood, Physician, TCAR

SUNNYVALE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE® Transcarotid Neuroprotection System PLUS (“NPS PLUS”), a key component of the TCAR® portfolio.

Key Points: 
  • SUNNYVALE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE® Transcarotid Neuroprotection System PLUS (“NPS PLUS”), a key component of the TCAR® portfolio.
  • This next generation device builds upon the prior ENROUTE Transcarotid Neuroprotection System to deliver smoother arterial sheath insertion, greater flow precision, and a simplified prep experience for surgical teams, all while maintaining unparalleled neuroprotection during the TCAR procedure.
  • “With the launch of the NPS PLUS, we're thrilled to empower our TCAR-trained physicians with a solution that addresses their insights and feedback to further strengthen and streamline the TCAR procedure,” shared Chas McKhann, Chief Executive Officer of Silk Road Medical.
  • During TCAR, the surgical team inserts a tube-like sheath into the carotid artery and connects it to the ENROUTE Neuroprotection System, which temporarily reverses blood flow.

Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans

Retrieved on: 
Monday, April 1, 2024
CSF, Tmax, AUC, Patient, Cerebrospinal fluid, Cmax, Kinetics, APP, SILK

MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced the publication of new data from an earlier study supporting buntanetap as a translational inhibitor of amyloid precursor protein (APP) in patients with early Alzheimer’s Disease (AD).

Key Points: 
  • Buntanetap is an oral molecule that selectively binds to an iron-responsive element in the mRNA of APP and other neurotoxic proteins and inhibits their translation.
  • Through this mechanism, buntanetap was shown to decrease the production of amyloid beta (Aβ), a key hallmark in AD.
  • Here, SILK was used to measure the kinetics of APP in early AD patients and to quantify Aβ40 in CSF.
  • Notably, the analysis of adverse events demonstrated no dose-dependent effect of buntanetap compared to placebo, affirming the drug’s safety and tolerability.

Silk Road Medical Expands TCAR® Portfolio with Launch of Tapered ENROUTE® Transcarotid Stent System

Retrieved on: 
Tuesday, March 5, 2024
FACS, Hospital, MD, CEA, Professor, Physician, Vascular surgery, Stroke, Plaque, MBA, Risk, Cooper University Hospital, Silk, Patient, Anatomy, TCAR, Stenosis, SILK, Pharmaceutical industry

This launch expands upon the company’s prior ENROUTE Transcarotid Stent System, offering additional configurations to better tailor the Transcarotid Artery Revascularization (TCAR) procedure to patient anatomy.

Key Points: 
  • This launch expands upon the company’s prior ENROUTE Transcarotid Stent System, offering additional configurations to better tailor the Transcarotid Artery Revascularization (TCAR) procedure to patient anatomy.
  • “New tapered configurations for our ENROUTE Transcarotid Stent System build upon the robust portfolio of Silk Road’s carotid solutions.
  • The ENROUTE Transcarotid Stent System features an optimized cell design balancing lesion coverage and anatomical conformability for long-term plaque stabilization.
  • The stent system was purpose-built for TCAR with a short delivery system for ergonomic and precise stent delivery.

Silk Road Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Outlook

Retrieved on: 
Wednesday, February 28, 2024
Silk Road, CMS, Investment, Physician, Stroke, Adjustment, Risk, Growth, Webcast, Patient, TCAR, Stenosis, SILK, Video game

Gross profit for the fourth quarter of 2023 was $34.8 million compared to $29.1 million for the fourth quarter of 2022.

Key Points: 
  • Gross profit for the fourth quarter of 2023 was $34.8 million compared to $29.1 million for the fourth quarter of 2022.
  • Gross margin for the fourth quarter of 2023 increased to 74% compared to 73% for the fourth quarter of 2022, primarily due to an increase in production volumes.
  • Operating expenses were $49.2 million for the fourth quarter of 2023 compared to $41.7 million in the fourth quarter of 2022, which represents an increase of 18%.
  • ET on Wednesday, February 28, 2024, to discuss its fourth quarter and full year 2023 financial results.

Advancing Healthcare Access: Genesis MedTech Teams Up with Silk Road Medical to Serve Patients affected by Carotid Artery Disease in China

Retrieved on: 
Friday, March 8, 2024
Chinese Medical Doctor Association, Stroke, Neck, CEA, Physician, Common carotid artery, Carotid artery stenosis, Plaque, Risk, Splenic infarction, Genesis, Disability, Death, CNI, Cranial nerves, Health, Patient, Atherosclerosis, TCAR, Stenosis, Mortality, Medtech, SILK, Brain, Pharmaceutical industry

TCAR (Transcarotid Artery Revascularization) is an innovative minimally invasive surgical procedure used to treat carotid artery disease, a condition characterized by the narrowing or blockage of the carotid arteries in the neck.

Key Points: 
  • TCAR (Transcarotid Artery Revascularization) is an innovative minimally invasive surgical procedure used to treat carotid artery disease, a condition characterized by the narrowing or blockage of the carotid arteries in the neck.
  • Since its establishment in 2019, Genesis MedTech Group has continuously strived to enhance its peripheral interventional portfolio, offering comprehensive solutions to both physicians and patients.
  • Before the introduction of TCAR, moderate to severe carotid artery disease was generally treated clinically with two surgical methods: Carotid Endarterectomy (CEA) and Transfemoral Carotid Artery Stenting (TFCAS).
  • Together with Silk Road Medical, we remain dedicated to make better healthcare more accessible, improving patient care and outcomes."

Silk Road Medical to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Retrieved on: 
Wednesday, February 7, 2024
Stroke, SILK, Webcast, Risk

SUNNYVALE, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28th, 2024.

Key Points: 
  • SUNNYVALE, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28th, 2024.
  • Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Those interested in listening to the conference call should register online using this link .
  • Participants are encouraged to register more than 15 minutes before the start of the call.

Silk Road Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, December 20, 2023
Stroke, Conference, Risk, Interest, SILK

SUNNYVALE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • SUNNYVALE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference.
  • Management is scheduled to present on Wednesday, January 10, 2024 at 1:30 p.m. Pacific Time.
  • Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.silkroadmed.com/ .

Silk Road Medical (SILK) Stock Tanks After Revenues Lowered and CEO Leaves – Hagens Berman

Retrieved on: 
Tuesday, November 21, 2023
NCD, TCAR, Hagens Berman, SAN, News, Stroke, Person, Silk Road, Stenosis, FY, SILK

SAN FRANCISCO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Hagens Berman encourages Silk Road Medical, Inc. (NASDAQ: SILK) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Hagens Berman encourages Silk Road Medical, Inc. (NASDAQ: SILK) investors who suffered substantial losses to submit your losses now .
  • On Oct. 10, 2023, Silk Road announced, without explanation, that: (1) its Q3 2023 revenues were expected to be below Q2 revenues; and (2) it significantly reduced its expected FY 2023 revenues.
  • This news drove the price of Silk Medical shares down nearly 50% on Oct. 11, 2023.
  • “We’re focused on investors’ losses and investigating whether Silk Road may have misled investors about the effect of the NCD’s decision on TCAR-related revenues,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

Silk Road Medical (SILK) Investors with Substantial Losses Encouraged to Contact Hagens Berman, National Trial Attorneys: Firm Investigating Possible Securities Law Violations

Retrieved on: 
Monday, November 13, 2023
Hagens Berman, Stroke, Person, NCD, TCAR, Stenosis, News, FY, SILK, Silk Road, Pharmaceutical industry

On Oct. 10, 2023, Silk Road announced, without explanation, that: (1) its Q3 2023 revenues were expected to be below Q2 revenues; and (2) it significantly reduced its expected FY 2023 revenues.

Key Points: 
  • On Oct. 10, 2023, Silk Road announced, without explanation, that: (1) its Q3 2023 revenues were expected to be below Q2 revenues; and (2) it significantly reduced its expected FY 2023 revenues.
  • “We’re focused on investors’ losses and investigating whether Silk Road may have misled investors about the effect of the NCD’s decision on TCAR-related revenues,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Silk Road Medical and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .
  • Whistleblowers: Persons with non-public information regarding Silk Road Medical should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.